Select the search type
  • Site
  • Web
Search

Featured Fund

PB DYNAMIC ALLOCATION FUND (PBDYNAF)
Fund Objective
To achieve capital growth over the medium to long-term period by investing in equities and fixed income securities in domestic and foreign markets.
3-Year
Fund Volatility
11.7
moderate
Lipper Analytics
10 Oct 2020
Launch Date
19 June 2012
Performance of PBDYNAF vs its Benchmark Index Over the Following Periods Ended 30/10/2020
PBDYNAF (%) Benchmark (%) PBDYNAF (%) Benchmark (%)
Total Return Annualised Return
24.02 11.50 24.02 11.50
14.65 7.39 4.66 2.40
46.49 33.41 7.93 5.93
- - - -
92.58 79.64 8.20 7.30
*Source: Lipper, as at 30 Oct 2020
Performance of PBDYNAF and Benchmark Index (Since Fund Commencement* to 30/10/2020)
Benchmark: A composite of 70% MSCI AC Far East Ex-Japan Index and 30% 3-month Kuala Lumpur Interbank Offered Rates (KLIBOR)
* Commencement Date - 09 July 2012


  • PB Dynamic Allocation Fund (PBDYNAF or the Fund) seeks to dynamically allocate its portfolio across blue chip stocks and growth stocks listed on the domestic and foreign markets.
  • As at 30 October 2020, 91.2% of PBDYNAF’s net asset value (NAV) was invested in equities while 8.8% of NAV was invested in money market instruments. The Fund focused on sectors such as Technology, Communications, Consumer, Financial and Industrial in the U.S., China, Taiwan, Korea and the Netherlands.
  • From its commencement on 9 July 2012 up to 30 October 2020, the Fund registered a total return of +92.58% to outperform its benchmark’s return of +79.64%. This outperformance was led by its selected holdings of Technology and Healthcare stocks which benefited from the digitalisation trend and the continued rise in demand for quality healthcare.
  • For the 1-year, 3-year and 5-year periods ended 30 October 2020, the Fund also registered respective returns of +24.02%, +14.65% and +46.49% to outperform its benchmark’s respective returns of +11.50%, +7.39% and +33.41%.
  • Going forward, the Fund will look to continue investing in stocks that offer attractive growth prospects and resilient earnings growth, particularly within the Technology, Consumer and Healthcare sectors.


Our investment disclaimer can be viewed here.